Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report.
BACKGROUND
Dehydroepiandrosterone (DHEA) inhibits activation of nuclear factor kappa B (NF-kappaB), which is known to be activated in inflammatory lesions of ulcerative colitis, via PPARalpha. In a pilot trial DHEA was effective for the treatment of active ulcerative colitis. Pouchitis is a common complication after proctocolectomy for ulcerative colitis and still a therapeutical challenge.


METHODS
DHEA 200 mg/d was tested in chronic active pouchitis in a 35-year-old female patient. DHEA was given for eight weeks, and follow up for further eight weeks was performed. The number of stools dropped from 15-18/d to 8/d, the addition of mucus, which was observed initially, was absent during treatment. The consistence of stools improved from liquid/soft to soft/solid. Abdominal pain resolved and endoscopical signs of inflammation improved. Eight weeks after termination of treatment with DHEA, the patient again suffered from 12 to 18 soft to liquid stools per day and mild abdominal pain.


CONCLUSIONS
Therapeutic effects of DHEA in pouchitis should be evaluated systematically.
Klebl
F H
FH
Department of Internal Medicine I, University of Regensburg, Germany. frank.klebl@klinik.uni-regensburg.de
Bregenzer
N
N
Rogler
G
G
Straub
R H
RH
Schölmerich
J
J
Andus
T
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D003093:Colitis, Ulcerative / Q000601:surgery*; D003687:Dehydroepiandrosterone / Q000008:administration & dosage / Q000627:therapeutic use*; D004724:Endoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019449:Pouchitis / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D003687:Dehydroepiandrosterone